Teduglutide Safety, Efficacy Evaluated in Crohn's Disease Patients with Short Bowel Syndrome

Data on teduglutide efficacy for crohn's patients with short bowel syndrome has been limited due to rarity
Data on teduglutide efficacy for crohn's patients with short bowel syndrome has been limited due to rarity

Teduglutide (GattexNPS Pharmaceuticals) appeared safe and effective in patients with Crohn's disease with short bowel syndrome requiring parenteral support, a study published in the Journal of Clinical Gastroenterology reported.

Teduglutide is a glucagon-like peptide-2 analog currently indicated to treat adults with short bowel syndrome who are dependent on parenteral support. Real-world data is not readily available in patients with Crohn's disease and short bowel syndrome treated with teduglutide due to the rarity of short bowel syndrome. 

Related Articles

Researchers conducted a retrospective cohort study between 2012–2014 to evaluate the safety and efficacy of teduglutide in these patients. They obtained demographic, clinical, and therapeutic data from medical record systems. A total of 13 patients with Crohn's disease were included, of which 8 were on concomitant immunosuppression. At the start of teduglutide therapy, 69% were on parenteral nutrition and only one remained on parenteral nutrition at the end of follow-up. 

Prior to teduglutide, all patients were on intravenous fluids (IVF); median IVF was 9000mL weekly. IVF requirements reduced by a median of 3100mL weekly and 6 patients (46%) discontinued IVF. Treatment-related adverse events were obstructive symptoms, pancreatitis, asymptomatic lipase and amylase elevation, nausea, and abdominal pain. Four patients experienced catheter-related sepsis. 

Overall, treatment with teduglutide appeared safe and the majority of patients were weaned off parenteral support. 

For more information visit journals.lww.com.

Loading links....